Mostrar el registro sencillo del ítem

dc.contributor.authorFaria, Rita
dc.contributor.authorGomes, Manuel
dc.contributor.authorEpstein, David Mark 
dc.contributor.authorWhite, Ian R.
dc.date.accessioned2020-07-15T10:58:17Z
dc.date.available2020-07-15T10:58:17Z
dc.date.issued2014-07-29
dc.identifier.citationFaria, R., Gomes, M., Epstein, D., & White, I. R. (2014). A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics, 32(12), 1157-1170. [DOI 10.1007/s40273-014-0193-3]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/62984
dc.descriptionThe authors would like to thank Professor Adrian Grant and the team at the University of Aberdeen (Professor Craig Ramsay, Janice Cruden, Charles Boachie, Professor Marion Campbell and Seonaidh Cotton) who kindly allowed the REFLUX dataset to be used for this work, and Eldon Spackman for kindly sharing the Stata (R) code for calculating the probability that an intervention is cost effective following MI. The authors are grateful to the reviewers for their comments, which greatly improved this paper. M. G. is recipient of a Medical Research Council Early Career Fellowship in Economics of Health (grant number: MR/K02177X/1). I. R. W. was supported by the Medical Research Council [Unit Programme U105260558]. No specific funding was obtained to produce this paper. The authors declare no conflicts of interest.es_ES
dc.description.abstractMissing data are a frequent problem in cost-effectiveness analysis (CEA) within a randomised controlled trial. Inappropriate methods to handle missing data can lead to misleading results and ultimately can affect the decision of whether an intervention is good value for money. This article provides practical guidance on how to handle missing data in within-trial CEAs following a principled approach: (i) the analysis should be based on a plausible assumption for the missing data mechanism, i.e. whether the probability that data are missing is independent of or dependent on the observed and/or unobserved values; (ii) the method chosen for the base-case should fit with the assumed mechanism; and (iii) sensitivity analysis should be conducted to explore to what extent the results change with the assumption made. This approach is implemented in three stages, which are described in detail: (1) descriptive analysis to inform the assumption on the missing data mechanism; (2) how to choose between alternative methods given their underlying assumptions; and (3) methods for sensitivity analysis. The case study illustrates how to apply this approach in practice, including software code. The article concludes with recommendations for practice and suggestions for future research.es_ES
dc.description.sponsorshipMedical Research Council Early Career Fellowship in Economics of Health MR/K02177X/1es_ES
dc.description.sponsorshipMedical Research Council UK (MRC) U105260558es_ES
dc.description.sponsorshipMedical Research Council UK (MRC) MC_U105260558 MR/K02177X/1es_ES
dc.language.isoenges_ES
dc.publisherSpringeres_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.titleA Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trialses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1007/s40273-014-0193-3
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 3.0 España